A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms

被引:140
作者
Hammar, M [1 ]
Christau, S
Nathorst-Böös, J
Rud, T
Garre, K
机构
[1] Linkoping Univ Hosp, Fac Hlth Sci, Dept Obstet & Gynaecol, S-58185 Linkoping, Sweden
[2] Karolinska Hosp, Dept Obstet & Gynecol, S-10401 Stockholm, Sweden
[3] Organon AS, Skovlund, Denmark
来源
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY | 1998年 / 105卷 / 08期
关键词
D O I
10.1111/j.1471-0528.1998.tb10237.x
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To compare the effects of two postmenopausal regimens on menopausal symptoms, bleeding episodes, side effects and acceptability. Design Double-blind, randomised controlled trial. Setting Twenty-nine sites in Denmark, nine in Norway and six in Sweden. Participants Four hundred and thirty-seven postmenopausal women with menopausal complaints. None of these women had had a hysterectomy. Interventions Daily treatment with tibolone 2.5 mg (n = 218) or 17 beta-oestradiol 2 mg plus norethisterone acetate 1 mg (E-2/NETA) (n = 219). Main outcome measures Hot flushes, sweating episodes, vaginal dryness, assessment of sexual life and bleeding patterns; at baseline and after 4, 12, 24 and 48 weeks. Results Treatment with either preparation significantly reduced mean scores for hot flushes, sweating episodes and vaginal dryness. The overall discontinuation rate was 28% (tibolone 25%, E-2/NETA 31%; P = 0.14), mostly during the first six months. There was a markedly lower cumulative incidence of bleeding or spotting episodes with tibolone compared with E-2/NETA (P < 0.0001), mainly during the first six treatment cycles. Conclusions Both tibolone and E-2/NETA effectively alleviate menopausal symptoms. However, tibolone caused significantly fewer bleeding or spotting episodes, which were reflected by lower overall rates of bleeding, as well as lower drop-out rates due to bleeding.
引用
收藏
页码:904 / 911
页数:8
相关论文
共 43 条
  • [1] WOMENS OPINION ON WITHDRAWAL BLEEDING WITH HORMONE REPLACEMENT THERAPY
    BARENTSEN, R
    GROENEVELD, FPMJ
    BAREMAN, FP
    HOES, AW
    DOKTER, HJ
    DROGENDIJK, AC
    [J]. EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1993, 51 (03): : 203 - 207
  • [2] BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062
  • [3] CORTESPRIETO J, 1987, MATURITAS, P67
  • [4] MENOPAUSAL THERAPY AND ENDOMETRIAL PATHOLOGY
    CRAFT, I
    SWINHOE, J
    MUGGLESTONE, CJ
    [J]. BRITISH MEDICAL JOURNAL, 1978, 2 (6134) : 429 - 430
  • [5] DEVISSER J, 1984, ARZNEIMITTELFORSCH, V34-2, P1010
  • [6] PERIMENOPAUSAL WOMENS VIEWS ON TAKING HORMONE REPLACEMENT THERAPY TO PREVENT OSTEOPOROSIS
    DRAPER, J
    ROLAND, M
    [J]. BRITISH MEDICAL JOURNAL, 1990, 300 (6727) : 786 - 788
  • [7] EGARTER C, 1995, MENOPAUSE NEUE ERKEN, P6
  • [8] Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein(a) and LDL subfractions
    Farish, E
    Spowart, K
    Barnes, JF
    Fletcher, CD
    Calder, A
    Brown, A
    Hart, DM
    [J]. ATHEROSCLEROSIS, 1996, 126 (01) : 77 - 84
  • [9] EFFECTS OF TIBOLONE ON LIPOPROTEIN(A) AND HDL SUBFRACTIONS
    FARISH, E
    BARNES, JF
    ROLTON, HA
    SPOWART, K
    FLETCHER, CD
    HART, DM
    [J]. MATURITAS, 1994, 20 (2-3) : 215 - 219
  • [10] Short term blood pressure and metabolic effects of tibolone in postmenopausal women with non-insulin dependent diabetes
    Feher, MD
    Cox, A
    Levy, A
    Mayne, P
    Lant, AF
    [J]. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1996, 103 (03): : 281 - 283